Skip to main
EOLS
EOLS logo

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 31%
Hold 8%
Sell 0%
Strong Sell 8%

Bulls say

Evolus Inc. reported a significant 29.4% year-over-year increase in total net revenue, totaling $78.9 million in 4Q23, driven largely by higher volumes of its key product, Jeuveau. The company also experienced impressive account growth, with approximately 830 new accounts purchasing Jeuveau in the quarter, surpassing the quarterly average by 20%. Additionally, the imminent launch of the Evolysse fillers, projected to contribute 8-10% to total revenue for FY 2025, reflects a strong strategic position, bolstered by favorable market trends among younger consumers toward aesthetic treatments.

Bears say

Evolus Inc. reported a 4Q23 GAAP net loss of $6.8 million, translating to a loss per share of $0.11, which exceeded internal estimates and fell short of the consensus forecast. The company also faces significant operational challenges, including reliance on third-party suppliers for its product Jeuveau, contributing to a heightened risk of supply chain disruptions and increased operating expenses. Additionally, competitive pressures in the cash-pay aesthetic market, alongside potential financing risks and the lingering effects of COVID-19, further exacerbate Evolus's challenges, creating a negative outlook for its stock performance.

Evolus (EOLS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 31% recommend Buy, 8% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Buy based on their latest research and market trends.

According to 13 analysts, Evolus (EOLS) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.